Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (DE:HAZ)
FRANKFURT:HAZ
Holding DE:HAZ?
Track your performance easily
HAZ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€65.00 - €89.50
Previous Close€69.5
Volume0.00
Average Volume (3M)82.00
Market Cap
€3.59B
Enterprise Value€4.39B
Total Cash (Recent Filing)$344.43M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 07, 2024EPS Estimate
€0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,177,734
10 Day Avg. Volume0
30 Day Avg. Volume82
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)2.91
Price to Cash Flow (P/CF)-35.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit6.35
Enterprise Value/Ebitda16.82
Forecast
1Y Price Target
€97.96Price Target Upside40.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Haemonetics News
Bulls Say, Bears Say
Bulls Say
Market Leadership In Plasma CollectionHaemonetics is well-positioned to continue to remain the market leader in the attractive and fast-growing plasma collection space.
Product Innovation And Market ExpansionGoing forward, HAE to benefit from the recent launch of the larger VASCADE MVP XL which should give the company more exposure to the pulse field ablation and left atrial appendage closure (LAAC) markets, both growing 20+%.
Strong Financial Performance And Growth ProspectsThe medical device maker primarily focused on plasma collection and vascular closure should benefit from strong underlying market growth trends which should ultimately help to expand margins.
Bears Say
Business PerformanceThe plasma business experienced a decline of 2.7% on a reported basis and 2.6% organically, indicating struggles in maintaining growth.
Financial PerformanceHAE's operating margin decreased by 150 basis points year-over-year, suggesting challenges in maintaining profitability.
Investor ConfidenceHAE shares have declined approximately 15% since fiscal Q1 results, reflecting shaken investor confidence in market expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.16% Insiders
49.07% Mutual Funds
0.20% Other Institutional Investors
25.11% Public Companies and
Individual Investors
HAZ FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was €65.00 and its highest was €89.50 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 07, 2024 which is in 19 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 08, 2024. The company reported €0.932 earnings per share for the quarter, beating the consensus estimate of €0.918 by €0.014.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is €0.98.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 51,177,734 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of €0.932 in its last earnings report, beating expectations of €0.918. Following the earnings report the stock price went down -1.282%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 98M.
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€97.96 (40.95% Upside)
€97.96 (40.95% Upside)
Blogger Sentiment
Bullish
DE:HAZ Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.43%
12-Months-Change
Fundamentals
Return on Equity
12.98%
Trailing 12-Months
Asset Growth
29.49%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAZ Earnings Call
Q1 2024
0:00 / 0:00
---
HAZ Stock 12 Month Forecast
Average Price Target
€97.96
▲(40.95% Upside)
Technical Analysis
Best Analysts Covering HAZ
1 Year
1 Year Success Rate
27/46 ratings generated profit
1 Year Average Return
+8.38%
reiterated a buy rating 5 months ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 58.70% of your transactions generating a profit, with an average return of +8.38% per trade.
---